Evidence map›Paper›PMID 27906745›Full record

ArticleClinical obstetrics and gynecology2017

Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Caroline C Marrs, Maged M Costantine

Abstract read
In one paragraph

Article in Clinical obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Importance of STAT3 signaling in preeclampsia (Review).International journal of molecular medicine · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Challenges in conducting clinical research studies in pregnant women.Journal of pharmacokinetics and pharmacodynamics · 2020
    Review
  8. Review
  9. Dyslipidemia and the role of adipose tissue in early pregnancy in the BPH/5 mouse model for preeclampsia.American journal of physiology. Regulatory, integrative and comparative physiology · 2019
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caroline C MarrsDepartment of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, The University of Texas Medical Branch, Galveston, Texas.
Maged M Costantine
The University of Texas Medical Branch at Galveston · US

Funding

UTMB OPRC Administrative CoreU54HD047891 · NICHD · UNIVERSITY OF TEXAS MED BR GALVESTON · PI DUKES, KIMBERLY A. · 2015 to 2019
$4.8M
NICHD NIH HHS U54 HD047891
6 · The paper itself

Abstract

Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

Indexed as

AspirinFemaleFibrinolytic AgentsHumansPravastatinPre-EclampsiaPregnancyRisk FactorsAspirinFibrinolytic AgentsPravastatin

Identifiers

PMID27906745
PMCPMC5250542
OpenAlexW2558901640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.